An encouraging new treatment for binge eating disorder was announced on May 3, 2012 with exciting preliminary results in the Phase II clinical trial. An opioid antagonist nasal spray has been created by the Lightlake Therapeutics Inc. A double-blind, placebo-controlled, randomized, six month Phase II trial enrolled 127 subjects for the treatment of BED (binge eating disorder). The behavior had little change in the beginning of the study, however, the effect of the nasal spray created an extinction curve over time where the benefits improved. Dr. Roger Crystal, M.D., CEO of Lightlake Therapeutics Inc. states “Lightlake is committed to research that can help us advance our treatment of BED and other addictive behavior disorders that affect millions of individuals worldwide. The data provides further evidence that Naloxone may also be a promising treatment for Bulimia Nervosa.” To read further on this thrilling research, read the attached article.
Hannah Chase
Intern at Eating Disorder Hope
Wednesday, June 6, 2012
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment